AVA NP 695
Alternative Names: AVA-NP-695Latest Information Update: 08 Jul 2026
At a glance
- Originator Avammune Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 22 Apr 2026 Pharmacodynamics data from a preclinical trial in Solid tumours presented at the 117th Annual Meeting of the American Association for Cancer Research (AACR-2026)
- 25 Apr 2025 Pharmacodynamics data from a preclinical trial in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 30 May 2023 Avammune Therapeutics has patent pending for "2-amino-s6-substituted thiopurine compounds as inhibitors of the enpp1 protein" in South Korea, China, Australia, Japan, Canada, Brazil, USA, Europian union and Israel